

# CANCER MODELLING MEETING

Santiago de Compostela

21 JUNE

roche-chus.es

Link to  
[registration form](#)




# CANCER MODELLING MEETING



## Venue

Theatre Room, *Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS)*, Santiago de Compostela.

**09:30** Welcome and introduction to the Roche-Chus Joint Unit



## SESSION I

### IN SILICO APPROACHES TO ONCOLOGY RESEARCH


**09:45** *Modelling the Complexity of Drug Resistance in Cancer.*

Dr. Arturo Alvarez-Arenas Alcamí  
*Mathematical oncology Laboratory, MòLAB. Universidad de Castilla-La Mancha, UCLM. Ciudad Real (Spain).*

**10:30** *In silico models of cancer cell metastasis: from local invasion to extravasation.*

Dr. José Manuel García Aznar  
*Multiscale in Mechanical and Biological Engineering. Universidad de Zaragoza. Zaragoza (Spain).*

**11:15** *Coffe break.*



## SESSION II

### UNDERSTANDING TUMOUR NICHE THROUGH IN VITRO MODELS

**11:45** *3D cell culture strategies to model cancer microenvironment dynamics.*

Dr. Catarina Brito  
*Advanced Cell Models Laboratory, Instituto de Biologia Experimental e Tecnológica, iBET; ITQB Nova. Oeiras (Portugal).*


**12:30** *TGF $\beta$  drives immune evasion in genetically reconstituted colon cancer metastasis.*

Dr. Daniele Tauriello  
*Colorectal cancer laboratory, Institute for Research in Biomedicine, IRB Barcelona (Spain).*

**13:15** *Interplay between senescence and reprogramming, and its implications for cancer.*

Dr. Manuel Serrano  
*Cellular Plasticity and Disease, Institute for Research in Biomedicine, IRB Barcelona (Spain).*

**14:00** *Lunch.*



## SESSION III

### ANIMAL MODELS IN CANCER RESEARCH

**15:00** *Patient derived orthoxenografts for the development of personalize oncology strategies.*

Dr. Alberto Villanueva  
*Chemoresistance and Predictive Factors Laboratory, Instituto de Investigación Biomédica de Bellvitge, IDIBELL (Spain).*

**15:45** *A zebrafish xenograft platform to predict tumour aggressiveness and responses to chemotherapy in breast cancer patients.*

Dr. Maria Luisa Cayuela  
*Telomerase, Aging and Cancer Group, Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca, IMIB. Murcia (Spain).*

**16:30** *Development of a functional assay for personalised chemotherapy using zebrafish.*

Dr. Miguel Godinho Ferreira  
*Telomeres and Genome Stability Group. Instituto Gulbenkian de Ciência. Oeiras (Portugal).*